Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Hemasphere
Hoofdauteurs: Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wolters Kluwer Health 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://ncbi.nlm.nih.gov/pubmed/32647793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000363
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items